Some clinical Ab drugs have also been reported to elicit an anti‐Id Ab response after treatment, such as the targeted cancer drug Campath (anti‐CD52 Ab) and the immunosuppressant drug Remicade (anti‐TNFɑ Ab).15, 46, 47. The gene discussed is CD52; the disease is cancer.